The Rare Cancers Bill, which is promoted by Edinburgh South West MP, Dr Scott Arthur, has passed its Second Reading in the House of Lords.
The legislation is intended to tackle gaps in research, treatment development and access to clinical trials for people affected by this group of rare and less common cancers. Together these make up almost half of the diagnoses in the UK, but treatment can be limited and survival rates poor. Some of this is down to delayed diagnosis.
Prompted by his father-in-law’s death from a brain tumour, Dr Arthur chose this as his first Private Member’s bill after being elected. He has teamed up with more than 40 charities to reflect the concerns of patients as well as doctors.
The bill would:
- establish a named national lead for rare cancer research to improve accountability and coordination
- require the Government to review the UK’s orphan drug regulations to better support the development of treatments for rare cancers
- improve the sharing of cancer registry data across the UK, helping more patients take part in clinical trials
Dr Arthur said: “I am delighted that the Rare Cancers Bill has passed its Second Reading in the House of Lords. This is an important milestone for patients and families who have waited far too long for rare cancers to receive the attention, coordination and investment they deserve.
This Bill is about putting responsibility where it belongs, improving how research is led and coordinated, and making it easier for patients to access clinical trials that could transform outcomes.”
Laura Challinor, Senior Policy Manager at Blood Cancer UK, said: “Rare and less common cancers make up nearly half of all cancer diagnoses in the UK, yet they’re responsible for the majority of cancer deaths. Developing new treatments is vital for people with blood cancers including those with leukaemia, lymphoma and myeloma.
“This Bill is a vital step forward. It could unlock more research into these diseases, helping to ensure outcomes for those with rare cancers improve. We’re encouraged by the progress so far and are grateful to the blood cancer community whose voices are helping to keep this Bill moving.”
The Second Reading in the Lords is the first time the members of the Lords have debated the principles and main purpose behind the bill. At this point they can highlight any concerns or specific areas where changes will be needed. The bill now proceeds to the Committee stage and will be examined line by line.
